---
schema_version: "secwatch.filing_event.v1"
accession: "0001472375-25-000103"
form_type: "8-K"
ticker: "RGPX"
cik: "0001357878"
company_name: "REGENEREX PHARMA, INC."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:28:14.021339+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regenerex Pharma enters exclusive collagen supply deal with Holista; minimum purchases ramp to $9M/yr

## Summary
- Exclusive worldwide rights to Holista's ovine collagen for wound care; initial focus on U.S. market.
- Minimum purchase commitments: $50k in 2025, $3M in 2026, $6M in 2027, $9M annually from 2028.
- Regenerex to fund clinical studies and FDA regulatory approvals for advanced wound care products.
- Joint collaboration on nano-collagen applications with shared IP ownership.
- Agreement runs for life of patents; can be terminated on 90 days' notice or for breach/insolvency.

## SEC filing metadata
- accession: 0001472375-25-000103
- form_type: 8-K
- ticker: RGPX
- cik: 0001357878
- company_name: REGENEREX PHARMA, INC.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357878/000147237525000103/0001472375-25-000103-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357878/000147237525000103/ixform8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001472375-25-000103
- JSON: https://secwatch.observer/filing/0001472375-25-000103.json
- Plain text: https://secwatch.observer/filing/0001472375-25-000103.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.